← Leaderboards
Derek C Angus
University Of Pittsburgh At Pittsburgh
$17,409,826
Attributed
$19,994,848
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$31,157,523 · 9
AHRQ$0 · 1
By mechanism
P50$16,884,622 · 4
R01$11,729,081 · 4
U01$2,385,431 · 1
R34$158,389 · 1
Top collaborators
- Donald M Yealy8 shared
- Sachin Yende5 shared
- Richard Samuel Hotchkiss1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Hilary A. Tindle$15,133,646
- Michael A Pulsipher$13,522,310
- Hulya Bayir$16,376,338
- Annette J De Vito Dabbs$9,711,367
- Maria Mori Brooks$44,871,550
Others in their field
Top investigators on “Caring”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$305,871,236
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$279,179,778
- Chanza Baytop · Westat, Inc.$271,217,917
- Larry Arthur$256,720,406
Research focus
CaringSeptic ShockPatient CareClinical ResearchProtocols DocumentationResuscitationEnrollmentDesignProspectiveFutureRandomizedAmericanOutcomes ResearchBiological MarkersUniversitiesCollaborationsAdult Respiratory Distress SyndromeCost EffectivenessResearch PersonnelLung InjuryRiversInflammationInnovationMortality Vital Statistics
Grant awards (49)
Precision Medicine Approach to Glucocortisteroids in Sepsis$621,198
R01 · FY2024 · GM
Precision Medicine Approach to Glucocortisteroids in Sepsis$639,291
R01 · FY2023 · GM
Precision Medicine Approach to Glucocortisteroids in Sepsis$649,030
R01 · FY2022 · GM
Precision Medicine Approach to Glucocortisteroids in Sepsis$663,908
R01 · FY2021 · GM
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh$324,285
U01 · FY2020 · HL
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh - Supplement$322,741
U01 · FY2020 · HL
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh$324,285
U01 · FY2019 · HL
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh$315,363
U01 · FY2018 · HL
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh$315,363
U01 · FY2017 · HL
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh$315,363
U01 · FY2016 · HL
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh$323,929
U01 · FY2015 · HL
Immunotherapy of sepsis using anti-PDL1 antibody$158,389
R34 · FY2015 · GM
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh$144,102
U01 · FY2014 · HL
Protocolized Care for Early Septic Shock (ProCESS)$313,964
P50 · FY2012 · GM · contact PI
Protocolized Care for Early Septic Shock (ProCESS)$407,271
P50 · FY2011 · GM · contact PI
Protocolized Care for Early Septic Shock (ProCESS)$507,552
P50 · FY2010 · GM · contact PI
Costs and Cost Effectiveness$250,452
P50 · FY2010 · GM · contact PI
Mechanisms of Action$23,156
P50 · FY2010 · GM · contact PI
Clinical Efficacy$21,532
P50 · FY2010 · GM · contact PI
Protocolized Care for Early Septic Shock (ProCESS)$2,314,994
P50 · FY2009 · GM · contact PI
Protocolized Care for Early Septic Shock (ProCESS)$1,948,857
P50 · FY2009 · GM · contact PI
Clinical Efficacy$975,185
P50 · FY2009 · GM · contact PI
Mechanisms of Action$341,282
P50 · FY2009 · GM · contact PI
Costs and Cost Effectiveness$221,860
P50 · FY2009 · GM · contact PI
Protocolized Care for Early Septic Shock (ProCESS)$1,711,416
P50 · FY2008 · GM · contact PI
Clinical Efficacy$953,348
P50 · FY2008 · GM · contact PI
Mechanisms of Action$296,616
P50 · FY2008 · GM · contact PI
Costs and Cost Effectiveness$131,012
P50 · FY2008 · GM · contact PI
Protocolized Care for Early Septic Shock (ProCESS)$1,693,937
P50 · FY2007 · GM · contact PI
Clinical Efficacy$1,003,370
P50 · FY2007 · GM · contact PI
Long-Term Outcomes of NO for Ventilated Premature Babies$647,031
R01 · FY2007 · HL · contact PI
Mechanisms of Action$252,708
P50 · FY2007 · GM · contact PI
Costs and Cost Effectiveness$61,898
P50 · FY2007 · GM · contact PI
Protocolized Care for Early Septic Shock (ProCESS)$2,264,684
P50 · FY2006 · GM · contact PI
Clinical Efficacy$885,525
P50 · FY2006 · GM · contact PI
Long-Term Outcomes of NO for Ventilated Premature Babies$618,699
R01 · FY2006 · HL · contact PI
Mechanisms of Action$253,706
P50 · FY2006 · GM · contact PI
Costs and Cost Effectiveness$50,297
P50 · FY2006 · GM · contact PI
Long-Term Outcomes of NO for Ventilated Premature Babies$633,688
R01 · FY2005 · HL
Genetic And Inflammatory Markers Of Sepsis$702,406
R01 · FY2004 · GM
Long-Term Outcomes of NO for Ventilated Premature Babies$599,346
R01 · FY2004 · HL
Economic Analysis of Pulmonary Artery Catheter Use$0
R01 · FY2004 · HS
Genetic And Inflammatory Markers Of Sepsis$817,169
R01 · FY2003 · GM
Long-Term Outcomes of NO for Ventilated Premature Babies$688,553
R01 · FY2003 · HL
Economic Analysis of Pulmonary Artery Catheter Use$0
R01 · FY2003 · HS
Genetic And Inflammatory Markers Of Sepsis$1,376,430
R01 · FY2002 · GM
Economic Analysis of Pulmonary Artery Catheter Use$0
R01 · FY2002 · HS
Genetic And Inflammatory Markers Of Sepsis$3,072,332
R01 · FY2001 · GM
Economic Analysis of Pulmonary Artery Catheter Use$0
R01 · FY2001 · HS